LKL International Berhad Temettü

Temettü kriter kontrolleri 0/6

LKL International Berhad does not currently pay a dividend.

Anahtar bilgiler

Temettü verimi

-2.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2.0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	RM 0.035
Ödeme oranı	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Is LKL International Berhad (KLSE:LKL) Using Too Much Debt?

Oct 07

Investors Aren't Entirely Convinced By LKL International Berhad's (KLSE:LKL) Revenues

Jun 14

Is LKL International Berhad (KLSE:LKL) Weighed On By Its Debt Load?

Mar 29

We're Watching These Trends At LKL International Berhad (KLSE:LKL)

Feb 14

What Type Of Shareholders Own The Most Number of LKL International Berhad (KLSE:LKL) Shares?

Jan 10

LKL International Berhad (KLSE:LKL) Could Easily Take On More Debt

Dec 14

If You Had Bought LKL International Berhad (KLSE:LKL) Stock A Year Ago, You Could Pocket A 773% Gain Today

Nov 27

Should You Be Impressed By LKL International Berhad's (KLSE:LKL) Returns on Capital?

Aug 03

Should You Use LKL International Berhad's (KLSE:LKL) Statutory Earnings To Analyse It?

Jul 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if LKL's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if LKL's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

LKL International Berhad Piyasaya Karşı Temettü Getirisi

LKL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LKL)	0%
Pazarın Alt %25'i (MY)	2.0%
Pazarın En İyi %25'i (MY)	4.8%
Sektör Ortalaması (Medical Equipment)	1.4%
Analist tahmini (LKL) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate LKL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate LKL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LKL is not paying a notable dividend for the MY market.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as LKL has not reported any payouts.

LKL International Berhad Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Is LKL International Berhad (KLSE:LKL) Using Too Much Debt?

Second quarter 2024 earnings released: RM0.006 loss per share (vs RM0.22 loss in 2Q 2023)

New major risk - Market cap size

LKL International Berhad Appoints Lim Pak Hong as Executive Director

First quarter 2024 earnings released: RM0.019 loss per share (vs RM0.22 loss in 1Q 2023)

New minor risk - Financial position

LKL International Berhad Announces Resignation of Datuk Chong Loong Men as Executive Director

LKL International Berhad, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: RM0.022 loss per share (vs RM0.18 loss in FY 2022)

New major risk - Market cap size

New minor risk - Financial data availability

New minor risk - Share price stability

New minor risk - Share price stability

Investors Aren't Entirely Convinced By LKL International Berhad's (KLSE:LKL) Revenues

LKL International Berhad Appoints Haji Mohd Yazid Bin Haji Mustafa as Independent and Non Executive Chairman

LKL International Berhad Appoints Winnie Goh Kah Mun as Joint Secretary

Is LKL International Berhad (KLSE:LKL) Weighed On By Its Debt Load?

LKL International Berhad Announces Resignation of Miss Sia Su Lin as Chief Financial Officer

High number of new and inexperienced directors

LKL International Berhad Announces Resignation of Mr. Tay Ben Seng, Benson as Executive Director, with Effect from May 30, 2022

Lkl International Berhad Announces Redesignation of Lim Ming Chang from Executive Director to Non Independent and Non Executive Director

Less than half of directors are independent

LKL International Berhad Reports Impairment Losses for the First Quarter Ended December 31, 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

LKL International Berhad, Annual General Meeting, Mar 15, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Financial Controller Chuen Wee has left the company

Full year 2021 earnings released: RM0.008 loss per share (vs RM0.01 profit in FY 2020)

Independent & Non-Executive Chairman Chaw Chen has left the company

Independent Non-Executive Director has left the company

LKL International Berhad Appoints Dato' Seri Dr. Chen Chaw Min as Independent and Non Executive Non Executive Chairman

New 90-day low: RM0.74

We're Watching These Trends At LKL International Berhad (KLSE:LKL)

New 90-day low: RM0.83

What Type Of Shareholders Own The Most Number of LKL International Berhad (KLSE:LKL) Shares?

Second quarter 2021 earnings released: RM0.002 loss per share

LKL International Berhad (KLSE:LKL) Could Easily Take On More Debt

New 90-day low: RM0.91

If You Had Bought LKL International Berhad (KLSE:LKL) Stock A Year Ago, You Could Pocket A 773% Gain Today

LKL International Berhad Appoints Lim Ming Chang as Executive Director

LKL International Berhad Appoints Datuk Chong Loong Men as Independent and Non Executive Member of Nomination Committee

Lkl International Berhad Announces Cessation of Tan Sri Datuk Adzmi Bin Abdul Wahab as Independent and Non Executive Member of Risk Committee

LKL International Berhad (KLSE:LKL) agreed to acquire 60% stake in Tahmaz Meditech Sdn Bhd from Ahmad Izhan Bin Abd Rashid, Andrew Suriady Sjoekoer, Chong Mei Ling, and Goventamal A/P Vadivelu.

Should You Be Impressed By LKL International Berhad's (KLSE:LKL) Returns on Capital?

New 90-day high - RM0.90

Should You Use LKL International Berhad's (KLSE:LKL) Statutory Earnings To Analyse It?

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin